Source: Ophthalmology
Area: News
One-year results from the DA VINCI Phase II study evaluating aflibercept (VEGF Trap-Eye versus photocoagulation in the treatment of diabetic macular oedema (DMO) have been published early online in Ophthalmology.
The study included 221 patients with centre-involved DMO who were randomised to one of four dosing regimens of aflibercept (0.5mg every four weeks; 2mg every four weeks; 2mg every eight weeks after three monthly doses; 2mg as need after three monthly doses) or macular laser photocoagulation. The primary endpoint was change in best-corrected visual acuity (BCVA) at 24 weeks; other outcomes assessed included the proportion of eyes that gained 15 letters or more in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA, and mean changes in central retinal thickness (CRT) from baseline at 52 weeks.
The 24-week outcomes were published in 2011 and these showed that aflibercept was more effective than laser photocoagulation in both preserving and ...
Uncategorized